At HemaCare, the health and safety of our employees, donors, customers, and community is a top priority. We are closely following the latest guidance regarding the novel coronavirus (COVID-19) from the CDC, WHO, local governments, and public health agencies, and will offer updates, should there be any developments, to this web page. For more information about HemaCare’s coronavirus prevention measures please visit:

As our Donor Center resumes operations, we have outlined in further detail the steps and guidelines we’ve introduced to protect the welfare of our donors, employees, and clients in the video below.

Overview of Regulatory Guidelines and Scientific Evidence Guiding Our COVID-19 Response

Video transcript

Business Operations Updates:


Below are some of the additional steps we are taking to protect the health and well-being of our donors and staff:

Prior to entering the facility, donor temperature will be measured, and additional screening questions asked to assess their risk of exposure to COVID-19.

Donors will be deferred for 28 days if they were in contact with COVID-19 positive or suspected patients, had a diagnosis of COVID-19 infection, were under self-quarantine orders, or show symptoms indicative of infection even if not tested.

Donors will be required to wear personal protective equipment (PPE) supplied by HemaCare while in the facility.
Protective barriers have been installed in the reception areas to supplement supplied PPE.

Seating areas have been clearly demarcated to ensure proper social distance is maintained.
Donors are screened and assessed for temperature again after entry using validated and calibrated thermometers.

Physical health exam including a health questionnaire and complete blood count (CBC) will be performed.

Donors will be asked to inform us immediately if they are diagnosed with or exposed to COVID-19 within the month following their donation.
Donor beds are spaced to adhere to social distancing guidelines and strict disinfection and sanitization of beds pre- and post-collection will be performed.

Protocols are in place to minimize the need to touch surfaces that have been touched by others including the management of entertainment equipment and snacks.
Employees have taken additional intensive safety training and are required to wear full PPE when at the facility.

We are performing frequent deep cleaning and disinfection activities throughout the day.

The number and location of hand sanitization stations have been increased throughout the facility.
We redesigned the donor experience to ensure proper social distancing guidelines are met as recommended by the CDC, specifically, maintaining six feet of space at all times.

Signs reminding visitors and employees to maintain distance at all times have been installed.

Support for Continuing Your Research During COVID-19

Keep your research on track with HemaCare’s inventory of cryopreserved material. Cryopreserved cellular materials provide you with the flexibility and consistency required during research and development, allowing you to plan studies according to your timeline.

As an essential business, HemaCare continues to supply researchers with a wide variety of high-quality cryopreserved leukopaks and primary cells such as mononuclear cells, stem cells, immune cells, and more from peripheral blood, bone marrow, and cord blood.

We are here to help you advance your research during these difficult times.

Browse Our Cryopreserved Products

In Need of COVID-19 Samples for Research?

Through our partners, we are proud to announce that we have access to the following COVID-19 samples:

  • Cryopreserved PBMCs (COVID-19 convalescent donors)
  • Cryopreserved plasma and serum (COVID-19 convalescent donors)
  • Cryopreserved immune cell subsets, including T cells (convalescent donors)
  • Whole blood (COVID-19 convalescent donors)
  • Frozen native stool sample

Each sample can be accompanied with basic donor demographic information (i.e. age, gender, ethnicity, etc.)

Request COVID-19 Samples

Please be advised that the various COVID-19 sources do change based on donor availability, infection rates, and availability of clinical teams. Therefore, sample requests are evaluated on a case-by-case basis.